



Single-use rapid assay for the detection of antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2)

- 90-1016 - 24 INSTI HIV-1/HIV-2 Antibody Tests with support materials (for POC use)
- 90-1015 - One INSTI HIV-1/HIV-2 Antibody Test with support materials (for POC use)
- 90-1014 - 24 INSTI HIV-1/HIV-2 Antibody Tests without support materials (for laboratory use only)

15°C \uparrow 30°C	Store at 15°C to 30°C	STERILE R	Sterilization using irradiation
	Caution	LOT	Lot number
	In vitro diagnostic medical device	REF	Catalogue number
	Consult instructions for use		Manufacturer
	Do not reuse		CE Mark
	Use by		R22 - Harmful if swallowed

15°C \uparrow 30°C Store at 15-30°C. For *in vitro* diagnostic use only.

It is recommended that the entire Package Insert be read prior to beginning the test procedure. Although the assay is designed to be simple to use, conformance with the test procedure is necessary to ensure accurate results.

INTENDED USE - Not for donor screening.

The INSTI HIV-1/HIV-2 Antibody Test is a single use, rapid, flow-through *in vitro* qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus Type 1 and Type 2 in human EDTA-whole blood, fingerstick blood, serum or EDTA-plasma. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as a diagnostic test capable of providing results in less than one minute. Although suitable for near-patient or point-of-care (POC) testing, the INSTI HIV-1/HIV-2 Antibody Test is not suitable for home testing. All required pre and post-test counseling guidelines must be followed in each setting in which the INSTI HIV-1/HIV-2 Antibody Test is used. The assay is packaged as a kit containing INSTI Membrane Unit, Sample Diluent, Color Developer, and Clarifying Solution with or without support materials (lancet , pipet and alcohol swab).

SUMMARY

Acquired Immunodeficiency Syndrome (AIDS) is caused by at least two retroviruses, HIV-1 and HIV-2. HIV-1 and HIV-2 are similar in genomic structure, morphology and ability to cause AIDS.¹ HIV is transmitted mainly by sexual contact, exposure to blood or blood products, or from an infected mother to her fetus. People with increased risk of HIV infection include hemophiliacs, intravenous drug-users and men having sex with men (MSM). HIV has been isolated from patients with AIDS, AIDS-related complex (ARC), and from persons at high risk of contracting AIDS.^{2,3} Antibodies specific for HIV envelope proteins are prevalent in sera from persons at high risk of contracting AIDS as well as in people with AIDS, or ARC.^{2,7} The presence of antibodies to HIV indicates previous exposure to the virus, but does not necessarily constitute a diagnosis of AIDS. The prevalence of antibodies to HIV in people not known to be at risk of acquiring HIV infection is unknown, but significantly less.⁸ Absence of antibodies to HIV does not indicate that an individual is absolutely free of HIV-1 or HIV-2; HIV has been isolated from seronegative individuals prior to seroconversion. Test specificity and sensitivity depend, amongst other factors, on: a) the selection of HIV antigens used for antibody detection, b) the classes of antibodies recognized by the detection conjugate, and c) complexity of the protocol used to perform the test.⁹

Non-specific reactions may be observed in some specimens. A reactive INSTI test result should be considered a preliminary result, with appropriate counseling provided in POC settings. Following a reactive rapid test result, a venous blood sample must be drawn in an EDTA collection tube (for whole blood or plasma) or a tube with no anticoagulant (for serum), and forwarded to a laboratory for HIV confirmatory testing.

PRINCIPLES OF THE TEST

The INSTI HIV-1/HIV-2 Antibody Test is a manual, visually read, flow through immunoassay for the qualitative detection of HIV-1/HIV-2 antibodies in human blood, serum or plasma. The test consists of a synthetic filtration membrane positioned atop an absorbent material within a plastic cartridge, referred to as the INSTI Membrane Unit. The membrane has been specifically treated with HIV-1 and HIV-2 recombinant proteins, which react with HIV-1/HIV-2 antibodies in the specimen to produce a distinct visual signal on the membrane. The membrane also includes a procedural control. The procedural control consists of a protein-A treated spot capable of capturing IgG antibodies normally present in blood and blood components. IgG antibodies react with a proprietary chromatic agent to produce a visual signal on the membrane. Since IgG antibodies are present in blood from normal or HIV positive human specimens, the control spot provides a visual signal when the test is run, indicating that the test was performed correctly. If the control spot does not appear, the test is considered invalid. In the case of the test spot, recombinant HIV-1 and HIV-2 proteins, embedded in the membrane, capture HIV specific antibodies, if present in the specimen. Antibodies captured in the test spot react with a proprietary chromatic agent to produce a visible signal on the membrane. The membrane unit is designed to filter, absorb, and retain the test specimen and all the test reagents in such a manner as to limit leakage and exposure of personnel to potentially infectious materials.

Reagents required to conduct a test include Sample Diluent, Color Developer and a Clarifying Solution. The test is performed by adding the blood, serum, or plasma specimen to the vial of Sample Diluent, which lyses the red blood cells. This specimen/diluent solution is then poured onto the well of the Membrane Unit. HIV-1/HIV-2 antibodies, if present in the specimen, are captured by proteins on the filtration membrane. Color Developer is then added to the Membrane Unit. The Color Developer reacts with the captured antibodies to generate a distinct blue dot at the location of the control spot and, in the case that HIV-1/HIV-2 antibodies are present in the specimen, a blue dot also appears at the location of the test spot on the membrane. In the final step, the Clarifying Solution is then added to the membrane to decrease

background color in order to make the control and test spots more distinct.

Antigen Selection: The INSTI HIV-1/HIV-2 assay utilizes a combination of recombinant transmembrane proteins from HIV-1 (gp41) and HIV-2 (gp36). Use of these proteins overcomes sensitivity and specificity problems associated with tests based on viral lysates or a combination of core antigen and other viral proteins.^{10,11}

Antibody Detection: The INSTI HIV-1/HIV-2 assay uses a unique reagent to detect antibodies to HIV-1 and/or HIV-2. Although primarily designed to detect the IgG class of specific antibodies, the INSTI HIV-1/HIV-2 assay has been shown to detect antibodies in samples obtained early in infection, during seroconversion, and low titer anti-HIV-1 samples obtained later in infection (see tables # 1, 2 and 3).

Test Complexity: The INSTI HIV-1/HIV-2 assay was designed to reduce protocol complexity. The INSTI HIV-1/HIV-2 assay does not require sample preparation, accurate timing, or several steps, which include multiple washes and reagents. These requirements increase the complexity of an assay and lead to procedural errors which may adversely affect sensitivity and specificity. Total test time may vary slightly depending on specimen type; but results of valid tests are always clearly readable within one to two minutes.

SPECIMEN COLLECTION AND STORAGE

- For EDTA-whole blood, EDTA-plasma or serum specimens, follow normal venipuncture blood collection procedures using a lavender-top EDTA anticoagulant tubes (for whole blood and plasma) or red-top (no anticoagulant) tubes for serum.
- If plasma or serum is to be used, separate from the blood cells by centrifugation.
- Serum or EDTA-plasma may be stored at 2-8°C for up to 5 days, stored frozen at -20°C for 3 months, or stored frozen at -70°C for one year.
- Whole blood specimens collected in EDTA anticoagulant may be stored at 4°C and should be tested within 48 hours. Do not heat or freeze whole blood specimens.
- Do not dilute prior to testing.

KIT COMPONENTS AND STORAGE

15°C \uparrow 30°C INSTI Reagents should be stored at 15-30°C. For 90-1015 all kit components are individually packaged for single use only. For 90-1014 and 90-1016 kits components are provided for 24 tests. Each kit contains the same number of each type of component. Each test requires the following materials:

- Membrane Unit, individually packaged, prepared with control (IgG capture) and test (gp41 and gp36 antigen) reaction spots. For single use only in the INSTI procedure.
- Sample Diluent vial - X_n R22, containing 1.5 ml of tris-glycine buffered solution containing cell lysis reagents, with adequate space for addition of blood, serum or plasma samples being tested with INSTI. Ready to use, no mixing or preparation required. Contains 0.1% sodium azide as a preservative. For single use only in the INSTI procedure. Stable to date and under storage conditions indicated on label.
- Color Developer vial - X_n R22, containing 1.5 ml of a blue-coloured Borate buffered proprietary indicator solution designed to detect IgG in the control spot and specific HIV antibodies in the test spot. For single use only in the INSTI procedure. Ready to use, invert 2-3X immediately before use. Contains 0.1% sodium azide as a preservative. Stable to date and under storage conditions indicated on label.
- Clarifying Solution vial - X_n R22, containing 1.5 ml of a proprietary tris-glycine buffered, proteinated clarifying solution designed to remove background staining from the membrane unit prior to reading the INSTI test results. Ready to use, no mixing or preparation required. For single use only in the INSTI procedure. Contains 0.1% sodium azide as a preservative. Stable to date and under storage conditions indicated on label.

SUPPORT MATERIALS

The following materials are required when testing fingerstick whole blood (included in 90-1016 and 90-1015 kits specified for point-of-care use.):

- Alcohol Swab
- Single-use Lancet (to be delivered sterile)
- Single-use Pipet, capable of dispensing 50µl

ESSENTIAL COMPONENTS REQUIRED BUT NOT PROVIDED:

INSTI HIV-1 TEST CONTROLS: Separate HIV-negative human serum substitute and HIV-1 positive defibrinated human plasma control samples product no. 80-1037 are available from bioLytical Laboratories in user-defined amounts, for use in quality control procedures. Please refer to the section on Quality Control, following the Assay Procedure, and the INSTI HIV-1 Test Controls package insert.

Personal protection equipment such as gloves, lab coat or gown.
Precision pipet capable of delivering 50µl of sample.
Appropriate biohazard waste containers.
Absorbent cotton balls for fingerstick or venipuncture wound closure.

For venipuncture blood collection:
Venipuncture apparatus if collecting blood samples.
Appropriate blood collection tubes.
Appropriate shipping containers.
Personal protective equipment.
Appropriate biohazard waste containers and disinfectants.

WARNINGS

For *in vitro* diagnostic use only.

It is recommended that the entire Package Insert be read prior to beginning the test procedure. Although the assay is designed to be simple to use, conformance with the test procedure is necessary to ensure accurate results.

- Do not mix reagents from different lots.
- Do not use reagents or kits beyond the stated expiration date.
- Do not use the Membrane Unit if the foil pouch has been previously opened or if the packaging integrity has been compromised. Once the Membrane Unit has been opened, it must be used immediately.
- Avoid microbial contamination of reagents.
- Sodium azide is present at 0.1% in all assay reagents. Sodium azide may react with lead or copper plumbing to form highly explosive metal azides. If products containing sodium azide are discarded into a drain, flush with large amounts of water to prevent azide build-up. Check with local regulatory agencies to determine at what concentration sodium azide may cause a product to be regulated as hazardous waste.
- The performance characteristics of the INSTI HIV-1/HIV-2 assay have not been established for body fluids other than EDTA whole blood, fingerstick blood, serum, and EDTA-plasma. The use of blood collected

in anticoagulants other than EDTA has not been validated. Insufficient data are available to interpret tests performed on other body fluids, pooled blood or pooled serum and EDTA-plasma, or products made from such pools.

7. Failure to use the recommended reagent and specimen volumes may result in leakage and/or overflow of liquids from the membrane unit.

△ 8. Patients that have been on long term antiretroviral drug therapy may result in false negative INSTI HIV-1/HIV-2 assay results.

9. Samples from patients with severe hypogammaglobulinemia conditions such as multiple myeloma may result in false negative or invalid results with INSTI.

PRECAUTIONS

△ 1. All specimens should be handled as if capable of transmitting infectious diseases. It is recommended that BioSafety Level 2 practices, or equivalent regulations, be observed.¹⁴

2. Thoroughly wash hands after handling or performing this test.

3. Do not smoke, eat, or drink in areas where specimens or kit reagents are being handled.

4. Wear a lab coat and disposable gloves while handling kit reagents or specimens. Do not pipet by mouth.

5. Avoid contact with skin and eyes. If contact occurs, wash affected areas with water.

6. Avoid forming aerosols.


△ 7. Dispose of all specimens and materials used to perform the test as if they contained infectious agents. The preferred method of disposal is sterilization by autoclaving for a minimum of one hour at 121°C followed by incineration. Liquid waste, not containing acid, and neutralized waste may be mixed with sodium hypochlorite in volumes such that the final mixture contains 0.5% sodium hypochlorite (a solution containing 10% household bleach). Allow at least 30 minutes for decontamination to be completed. Do not autoclave solutions that contain bleach.

8. Spills should be cleaned up and decontaminated in accordance with the user facility's established procedures for handling biohazardous spills.

ASSAY PROCEDURE

Note: All Test Units must be used immediately once opened. All reagents should be dispensed evenly in the center of the well.






FINGERSTICK BLOOD SAMPLE COLLECTION :


1. Gather support materials (swab, lancet , pipet), one sealed test pouch containing INSTI Membrane Unit, and one vial each of the Sample Diluent, Color Developer, and Clarifying Solution for each test to be performed.


Caution: The amount of sample (fingerstick blood) is critical. To ensure that the proper amount of blood is achieved, follow these instructions carefully:


2. Massage the finger to allow the blood to move to the surface (fingertip will become pink). Use heating pad if available to warm the hand. Hand must be positioned at waist level or lower.

3. Wipe the fingertip with the alcohol swab.

4. As soon as the finger is dry, remove the protective cap from the lancet . Press the finger firmly at the point just below where the lancet  will be applied. With the other hand, hold the lancet  by the body and lightly press the tip of the lancet  on the finger and then push down to release the needle (see diagram below). Immediately dispose the used lancet  into a proper sharps container.



5. As the blood bubbles up, hold the pipet horizontally and touch the tip of the pipet to the blood sample. Capillary action automatically draws the sample to the fill line and stops. If very little blood trickles out of the puncture, lightly squeeze the sides of the finger to release more blood or if blood flow is inadequate, perform a second skin puncture using a new lancet .



CAUTION! Filling is automatic: Never squeeze the tube while sampling.

6. Transfer the blood held in the pipet to the Sample Diluent vial (Solution 1). Align the tip of the pipet with the Sample Diluent vial and squeeze the bulb to dispense the sample (See Figure A). Note: If the sample will not expel, hold the pipet vertically and slide a finger over (without pressing) the vent hole, then squeeze the bulb (See Figure B). Recap the vial and mix by inversion. Follow steps 4-7 in the Test Procedure section below.




Figure A




Figure B

For EDTA whole blood, serum, EDTA-plasma and Kit Controls
Test Procedure:

1. Bring specimens to room temperature and mix each specimen thoroughly prior to use. Do not heat or repeatedly freeze/thaw specimens.

2. Gather one sealed test pouch containing INSTI Membrane Unit, and one vial each of the Sample Diluent, Color Developer, and Clarifying Solution for each test to be performed.

3. Using a pipet, add 50µl of whole blood, serum, plasma, or kit controls (see Note) to the Sample Diluent vial. Recap the vial and mix by inversion. Adding an excessive amount of specimen may cause the device to overflow or leak. Note: In POC settings, for INSTI kit controls, it is important to use a 50µl pipet device to add the control material to the Sample Diluent vial. Do not use the disposable single-use pipet provided for finger stick blood collection.

For all sample types:

4. Tear open the pouch and carefully remove the Membrane Unit without touching the center well. Place the unit on a level surface. For sample identification purposes the tab of the Membrane Unit may be labeled with the patient's name or number.

NOTE: At this point, it is important that the following steps be performed immediately and in sequence.

5. Remix the Sample Diluent-specimen mixture and pour the entire contents to the center of the Membrane Unit well. The sample should be absorbed through the membrane in less than 30 seconds; however, absorption times will vary slightly depending upon sample type.



6. Resuspend the Color Developer by slowly inverting to mix the solution thoroughly. Continue this process until careful visual observation confirms that the reagent is evenly suspended. Open the Color Developer and add the entire contents to the center of the Membrane Unit well. The colored solution should flow through completely in about 20 seconds.

7. Open the Clarifying Solution and add the entire contents to the center of the Membrane Unit well. This will lighten the background color and facilitate reading. Immediately read the result while the membrane is still wet. Do not read the results if more than 5 minutes has elapsed following the addition of Clarifying Solution.

QUALITY CONTROL

KIT CONTROLS:

The INSTI HIV-1/HIV-2 Antibody Test has a built-in IgG capture procedural control that demonstrates assay validity and adequate sample addition. A blue color in the control spot indicates that the proper specimen was added and that the assay procedure was performed correctly. The control spot will appear on all valid INSTI tests. (Refer to Interpretation of Results, below.)

INSTI HIV-1 Test Controls are available separately for use only with the INSTI HIV-1/HIV-2 Antibody Test. The controls are used to verify test performance and interpretation of results. Kit controls should be run under the following circumstances:

- with every batch of INSTI test run,
- for new INSTI user verification,
- when switching to new lot number of INSTI test kits.

Refer to the INSTI HIV-1 Test Controls package insert for additional information on the use of these reagents. It is the responsibility of each user of the INSTI HIV-1/HIV-2 Antibody Test to establish an adequate quality assurance program to ensure proper performance under their specific locations and conditions of use.

INTERPRETATION OF RESULTS

Do not read the results if more than 5 minutes has elapsed following the addition of Clarifying Solution.


INSTI HIV-1 TEST CONTROLS:

If using the control samples provided by bioLytical, all Positive controls must be reactive with INSTI and all Negative Controls must be non-reactive with INSTI. Controls that produce incorrect or invalid results must be re-tested with INSTI. If results are still incorrect or invalid, inform bioLytical Laboratories immediately.

NON-REACTIVE ▶ One blue dot that is clearly discernable above any background tint should appear on the membrane. This is the procedural Control Spot and shows that the test has been performed correctly. The control is located towards the top of the read frame furthest from the plastic tab on the Membrane Unit. No reaction should be visible at the test spot, located below the control. A non-reactive result indicates that antibodies to HIV-1/HIV-2 were not detected in the specimen.




REACTIVE ▶ Two blue dots that are discernable above any background tint indicate that the specimen contains HIV-1 and/or HIV-2 antibodies. One dot may be darker than the other. A sample giving this pattern is considered a preliminary reactive. Following a reactive rapid test result, a venous blood sample must be drawn in a lavender-top EDTA collection tube (for whole blood or plasma) or red-top tube (for serum), and forwarded to a laboratory for HIV confirmatory testing.



INVALID ▶ The test is invalid if any of the following occurs:


- A. There is no dot on the membrane
- B. The test dot appeared without the control dot
- C. Uniform tint across the membrane
- D. Only blue specks appear on the membrane



Note: Invalid tests with fingerstick blood samples in POC settings should be repeated with a fresh sample using a new membrane unit, kit components and support materials. Invalid tests with EDTA whole blood, EDTA plasma or serum samples in laboratory settings should be repeated using a new membrane unit and kit components.

INDETERMINATE ▶ The test is indeterminate if a faint background ring appeared on the test area

Following an indeterminate INSTI test result, a venous blood sample must be drawn in a lavender-top EDTA collection tube (for whole blood or plasma) or red-top tube (for serum) and forwarded to a laboratory for HIV confirmatory testing.



Please note the following:

- 1. Following a reactive or indeterminate INSTI test result, a venous blood sample must be drawn in a lavender-top EDTA collection tube (for whole blood or plasma) or red-top tube (for serum), and forwarded to a laboratory for HIV confirmatory testing.
- 2. Depending on the antibody titer, a reactive specimen may be less intense in color than the procedural control, or vice versa.
- 3. Only a solid blue spot of color discernibly darker than the background color should be interpreted as reactive or positive. In rare instances, a faint background ring may appear around the test spot; this should not be interpreted as a reactive result. Only tests exhibiting distinct fully formed blue test dot combined with a distinct fully formed blue control dot should be interpreted as reactive.
- 4. An invalid result indicates that the test was performed incorrectly or there is a problem with the sample

or device. The absence of a distinct control dot usually indicates that the sample volume was insufficient. An invalid test must be repeated.

5. A test resulting in a uniform blue tint across the entire membrane, thus obscuring the control and test spots, can occur when more than 60µl of whole blood is used and the flow through the assay membrane is obstructed.

6. An individual who has a non-reactive result but was involved in HIV-risk activity is likewise recommended to obtain additional testing over the next months.

7. To significantly reduce the risk of HIV transmission, it is advisable to refrain from high risk activities such as unprotected sex and needle sharing at all times.

LIMITATIONS OF THE TEST

Flow Times

In some instances, samples may exhibit longer than normal flow times (from the time the Sample Diluent-specimen mixture is poured in the membrane well to the time the Clarifying Solution has fully flowed through the membrane). This is due to variable factors such as cellular components, especially with whole blood. In instances of long flow times, a faint shadow in the form of a ring may appear at the test spot location, but this should not be interpreted as a reactive result. This should be considered as an indeterminate result. In these instances, a venous blood sample should be drawn in a lavender-top EDTA collection tube, and forwarded to a laboratory for HIV confirmatory testing.

The INSTI HIV-1/HIV-2 assay procedure and the interpretation of result must be followed closely when testing for the presence of antibodies to HIV in serum, plasma or whole blood.

Insufficient data are available to interpret tests performed on other body fluids, pooled blood or pooled serum and plasma, or products made from such pools; therefore, testing of these specimens is not recommended.

The INSTI HIV-1/HIV-2 assay has not been validated for detection of antibodies to HIV-1 Group O or N subtypes.

The INSTI HIV-1/HIV-2 assay detects antibodies to HIV-1/HIV-2 and is useful in establishing infection with HIV. Because a variety of factors may cause non-specific reactions, a patient found to be positive using the INSTI HIV-1/HIV-2 assay should have an EDTA blood sample drawn for laboratory-based confirmatory testing. A person who has antibodies to HIV is presumed to be infected with the virus and appropriate counseling and medical evaluation should be offered. The presence of HIV antibodies indicates past exposure to HIV but is not a diagnosis of AIDS, which can only be made by a physician. However, a non-reactive test does not rule out past exposure to HIV. The risk of an asymptomatic person with repeated reactive serum developing AIDS is not known. The prevalence of HIV infection in various groups, as well as clinical and public health guidelines, are available in the CDC Morbidity and Mortality Report.⁸ Samples from patients with severe hypogammaglobulinemia conditions such as multiple myeloma may result in false or invalid results with INSTI.

PERFORMANCE CHARACTERISTICS

Sensitivity and Specificity

The sensitivity of a test is the ability of a test to detect truly infected people; whereas, the specificity of a test is the ability of a test to identify all non-infected individuals. Thus, a sensitive test should not produce false negatives, and a specific test should not produce false positives. There is no single standard for detecting the sensitivity or specificity of an antibody test for HIV in human sera, plasma or whole blood. However, the generally accepted method to express the sensitivity and specificity of a given test in terms of the detection rate is to compare results to approved supplemental assay results, such as ELISA and Western Blot. Based on these criteria, the sensitivity and specificity of the INSTI HIV-1/HIV-2 assay were determined using matching fingerstick blood, EDTA whole blood, serum and EDTA-plasma samples, which were also analyzed for anti-HIV-antibodies using ELISA and Western Blot.

Samples tested using the INSTI HIV-1/HIV-2 test fall into 4 categories:

- Twenty five commercial seroconversion panels (Table 1) and one HIV-1 low titer antibody performance panel, (Table 3) which represent a wide range of antibody titers or classes.
- Canadian HIV seroconversion patient samples (Table 2)
- Prospective samples from HIV-positive patients enrolled in the Canadian Clinical Trial (Table 4)
- Prospective negative samples from patients enrolled in the Canadian Clinical Trial (Table 5)

bioLytical Laboratories' Canadian Clinical Trial data show:

- The relative sensitivity of the INSTI HIV-1/HIV-2 assay for early antibody detection was assessed using standardized seroconversion panels from Boston Biomedica Inc. Table 1 summarizes the INSTI HIV-1/HIV-2 assay data compared to a number of US licensed and European approved enzyme immunoassays (EIA) using the commercial panels.
- The relative sensitivity of the INSTI HIV-1/HIV-2 assay for early antibody detection was also assessed using Canadian seroconversion patients. Table 2 summarizes the data from the Canadian seroconversion patients.
- The sensitivity of the INSTI HIV-1/HIV-2 assay was ≥99% for fingerstick blood, EDTA blood, plasma and serum (range 99.0-99.6%) (Table 4). Indeterminate and invalid results were eliminated from evaluation.
- The specificity of the INSTI HIV-1/HIV-2 assay was ≥99.3% (range 99.3-100%) for fingerstick blood, EDTA blood, plasma and serum (Table 5). Indeterminate and invalid results were eliminated from evaluation.
- INSTI HIV-1/HIV-2 Antibody Test results were not affected by most potentially interfering conditions or substances as illustrated in Table 6. Samples from patients with severe hypogammaglobulinemia conditions such as multiple myeloma may result in false negative or invalid results with INSTI.

Table 1

Anti-HIV-1 Seroconversion Panel PRB-900 Series* Boston Biomedica Inc.

INSTI	Number of Panels
Detected earliest bleed of panel	14
Within 1 bleed of earliest EIA positive	8
Within 2 bleeds of earliest EIA positive	1
Unknown**	2

*PRB910, PRB904, PRB924, PRB912, PRB914, PRB916, PRB918, PRB922, PRB925, PRB926, PRB927, PRB928, PRB929, PRB934, PRB935, PRB944, PRB937, PRB938, PRB940, PRB941, PRB945, PRB947, PRB950, PRB952, PRB943

**The last bleed in the panel was positive by at least 1 EIA, negative by INSTI.

Anti-HIV-1 Seroconversion Panels PRB937 and PRB938

Table 2

Independent Study on the Performance of the INSTI HIV-1/HIV-2 Antibody Test on Canadian HIV Seroconversion Patients, n=34 patients from British Columbia and 20 from Alberta. A total of 85 serum or plasma samples collected after the initial HIV negative sample were tested in three laboratory centers:

INSTI	Licensed EIA		Western Blot			
	POS	NEG	POS	NEG	IND	Not done
POS	69 ¹	1	35	5	24	6
NEG	14 ²	0	0	10	4	0
IND	1 ²	0	0	1	0	0

1. 13/34 had low s/c ratios (<3.0) with licensed EIA.

2. s/c ratio with licensed EIA was low (5.64)

IND, Indeterminate

Table 3

INSTI HIV-1/HIV-2 Antibody Test Results for Anti-HIV-1 Low Titer Performance Panel #PRB-105* Boston Biomedica Inc.

Test	Specimen Number														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
INSTI	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Abbott EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Abbott HIVAB HIV-1/HIV-2 (rDNA)EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Cambridge Biotech Recombigen HIV-1 EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Syva EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Organon Teknika Vironostika Anti-HIV Uni-Form II	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Murex HIV 1/2 EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Ortho HIV-1/HIV-2 EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Sorin ETI-Ab-HIV 1/2K EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Syva Microtrak II EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Behringwerke ENZ PLUS Anti HIV 1/2 EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Biotest Anti-HIV-1/HIV-2 Recombinant EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Boehringer Mannheim Anti HIV-1/HIV-2 EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
IAF Biochem Detect-HIV EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Diagnostic Pasteur Genelavia EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
bioMerieux VIDAS anti-HIV-1/2 EIA	P	P	P	P	P	P	P	P	P	P	P	N	P	P	P
Murex Wellcozyme HIV-1/HIV-2 EIA	P	P	P	P	P	P	P	P	P	P	P	N	N	P	P
Behringwerke Enzygnost Anti HIV 1+2 EIA	N	P	N	P	P	P	P	P	P	P	P	N	P	P	P
Cellular Products HIV-1 EIA	N	P	P	P	P	P	P	P	N	P	P	N	P	P	P
Genetic Systems LAV EIA	N	P	P	P	P	P	P	P	N	P	P	N	P	P	P
Genetic Systems HIV-1/HIV-2 EIA	N	P	N	P	P	P	P	P	P	P	P	N	P	P	P
Organon Teknika HIV	N	P	N	P	P	P	P	P	N	P	P	N	P	P	P

*These samples were confirmed positive (P) by EIA and Western Blotting.

(Data obtained from Boston Biomedica package insert, May 1995 p.2)

Table 4

INSTI HIV-1/HIV-2 Sensitivity in matching fingerstick blood, EDTA whole blood, plasma and serum samples collected from patients (n=3507) enrolled in the Canadian Clinical Trial of INSTI.

	Fingerstick Blood	EDTA Whole Blood	Plasma	Serum
Number of Confirmed Positive Samples ¹	820	836	838	396 ²
Number of Positive Samples by INSTI HIV	817	831	834	392
Calculated Sensitivity (95% C.I.)	99.6% (98.9-99.9%)	99.4% (98.6-99.7%)	99.5% (98.8-99.8%)	99.0% (97.4-99.6%)
Positive Predictive Value of INSTI	97.84%	98.90%	99.90%	100%

1. Samples were confirmed HIV positive by the approved laboratory-based screen test of record, and by Western Blot.

2. Serum samples were collected from a portion (n=1346) of the study patients (n=3507)

Note: INSTI invalid results were not included in the table and calculations.

Table 5

INSTI HIV-1/HIV-2 Specificity in matching fingerstick blood, EDTA whole blood, plasma and serum samples collected from patients (n=3507) enrolled in the Canadian Clinical Trial of INSTI.

	Fingerstick Blood	EDTA Whole Blood	Plasma	Serum
Number of HIV Negative Samples ¹	2506	2630	2638	949
Number of Negative Samples by INSTI	2488	2621	2637	949
Calculated Specificity (95% C.I.)	99.3% (98.9-99.5%)	99.7% (99.4-99.8%)	99.96% (99.8-100%)	100% (99.6-100%)
Negative Predictive Value of INSTI	99.90%	99.80%	99.80%	99.58%

1. Samples were negative by the approved laboratory-based screen test of record.

Note: INSTI invalid results were not included in the table and calculations.

Table 6
INSTI HIV-1/HIV-2 Antibody Test Reactivity with Specimens from Individuals with potentially Interfering Medical Conditions and Specimens with Interfering Substances, n=388.

Specimen Type	INSTI Positive *	INSTI Negative **	Invalid
Anemia	1	2	
Carcinoma/Cancer	24	5	
Chlamydia	0	2	
Cytomegalovirus (CMV)	0	5	
Diabetes	17	6	
Epstein Barr Virus (EBV)	0	5	
Haemolysed	0	12	
Haemophilia	0	1	
Hepatitis A virus (HAV)	4	1	
Hepatitis B virus (HBV)	7	4	
Hepatitis C virus (HCV)	46	7	
Herpes	63	12	
HTLV I	0	7	
HTLV II	0	7	
Lipid Abnormalities	58	4	
Lymphoma	1	1	
MAC/TB	2	0	
Malaria	0	1	
Myeloma	0	7	3 ¹
Multiple Transfusion recipients	2	6 ²	-
Neuropathies	28	0	
PCP	2	0	
Rheumatoid Factor	0	5	
Rubella	0	5	
Lupus	0	5	
Syphilis	0	10	
Toxoplasmosis	1	10	
Yeast/Candida	0	2	

1. Weak or no IgG control spot visible
2. One sample was weak EIA positive but not confirmed.
*All INSTI Positive Samples were confirmed HIV Positive
**All INSTI Negative Samples were confirmed HIV Negative

HIV-2
The sensitivity of INSTI HIV-1/HIV-2 antibody test evaluated in an independent European study with 49 sera from Western Blot confirmed HIV-2 infected patients at the chronic stage of the infection was 100%. An additional study conducted in-house with 88 different HIV-2 positive serum and plasma samples obtained from European sources and added into individual whole blood (to simulate HIV-2 positive blood) also showed 100% sensitivity of INSTI for HIV-2 antibody detection.

HIV-1 Subtype Testing
Forty eight samples from 48 patients infected with HIV-1 non B strains were tested. All samples were genotyped by dideoxynucleotide sequencing of the entire HIV-1 protease gene and the first 450 codons of reverse transcriptase, for subtype determination. The subtype distribution was the following:

- A:7,
- C:8,
- D:8,
- F:6,
- G:8,
- J: 1,
- CRF AG: 5,
- CRF AE: 5

The sensitivity of the INSTI HIV-1/HIV-2 Antibody Test on the 48 non-B HIV positive samples tested was 100%.

Reproducibility
The reproducibility of the INSTI HIV-1/HIV-2 Antibody Test was tested at 3 laboratory sites using 3 lots of the INSTI device on 3 separate days. A panel of 9 blind-coded plasma samples, consisting of 4 antibody positive, 1 very low antibody level sample, and 4 antibody negative samples was tested at each site. A total of 729 tests were conducted, 243 at each site. For the 4 antibody positive and 4 antibody negative samples, the overall reproducibility was 99.7% (646/648, two antibody negative samples were read as weak positive at 1 site). For the 1 very low level antibody sample, 59% (48/81) of the results were positive while 41% (33/81) were negative.

BIBLIOGRAPHY

- Guyader, M., Emerman, M., Sonigo, P., et al. Genome organization and transactivation of the human immunodeficiency virus type 2. *Nature* 326:662-669, 1987.
- Blattner, W., Gallo, R.C., and Temin, A.M. HIV causes AIDS. *Science* 241:515, 1988.
- Curran, J.W., Morgan, W.M., Hardy, A.M., et al. The epidemiology of AIDS; Current status and future prospects. *Science* 229:1352-1357, 1985.
- Samgadharan, M.G., Popovic, M., Bruch, L., Schüpbach, J., and Gallo, R.C. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. *Science* 224:506-508, 1984
- Gallo, R.C., Salahuddin, S.Z., Popovic, M., et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. *Science* 224:500-503, 1984

- Weber, J.N., Weiss, R.A., Roberts, C., et al. Human immunodeficiency virus in two cohorts of homosexual men; Neutralising sera and association of anti-gag antibody with prognosis. *Lancet* 1:119-124, 1987
- Clavel, F., Gu(tard, D., Brun-V(zinet, F., et al. Isolation of a new human retrovirus from West African patient with AIDS. *Science* 233:343-346, 1986
- Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. *MMWR* 36 (suppl. no. 1S):1S-15S, 1987
- World Health Organization/Global Programme on AIDS. Report of a WHO workshop on synthetic peptides in HIV diagnosis and AIDS-related research, Moscow 24-26 May 1989. WHO Report, AIDS 1991, 5: WHO1-WHO9
- Los Alamos National Laboratory. Human retroviruses and AIDS Database. A compilation of nucleic acid and amino acid sequences, 1993.
- World Health Organization/Global Programme on AIDS. Operational characteristics of commercially available assays to detect antibodies to HIV-1 and/or HIV-2 in human sera. Geneva, Switzerland: WHO documents GPA/BMR/89.4; GPA/BMR/90.1; GPA/RES/DIA/90.1; GPA/RES/DIA/91.6; GPA/RES/DIA/92.8 and GPA/RES/DIA/93.4
- World Health Organization/Global Programme on AIDS. Acquired immunodeficiency syndrome (AIDS) proposed WHO criteria for interpreting results from Western blot assays for HIV-1, HIV-2 and HTLV-I/HTLV-II. *WHO Weekly Epidemiological Record* 65(37):281-282, 1990
- Malone, J.D., Smith, E.S., Sheffield, J., et al. Comparative evaluation of six rapid serological tests for HIV-1 antibody. *Journal of Acquired Immune Deficiency Syndrome (JAIDS)* 6:115-149, 1993
- The Laboratory Biosafety Guidelines 3rd Edition. Office of Laboratory Security, Health Canada. 3.1.2, 2004.

TECHNICAL INFORMATION
For further information or assistance, contact the Technical Services at 1 (604) 204-6784. For problem reporting, contact the Quality Assurance Department at 1 (604) 204-6784 ext.234.

PACKAGE INSERT LIMITED WARRANTY AND DISCLAIMER
Please read this limited warranty and disclaimer carefully before using the INSTI™ HIV-1/HIV-2 Antibody Test Kit (the "Kit"). By using this Kit, you agree with this disclaimer. Any user who does not agree to this disclaimer may not use this Kit and should return it to their point of purchase for a refund.

This Kit is warranted by bioLytical™ LABORATORIES Inc. to perform in substantial conformity with the information included in this Package Insert when used without material alteration in accordance with the instructions herein, until the earliest expiry date printed on any of the labels or materials included in this Kit. The sole obligation of bioLytical™ LABORATORIES Inc. and the user's exclusive remedy for breach of this warranty will be, at the sole option of bioLytical™ LABORATORIES Inc., to repair this Kit, replace this Kit or refund the amount paid for this Kit.

In the following disclaimer, "bioLytical" refers to bioLytical™ LABORATORIES Inc., its affiliates, distributors, and any persons acting on behalf of any of them.

Apart from the foregoing express warranty, bioLytical MAKES NO AND EXPRESSLY DISCLAIMS ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, REGARDING THIS KIT OR ANY INFORMATION, METHOD, PROCESS, PROCEDURE, CHEMICAL OR OTHER MATERIAL CONTAINED IN THIS KIT (THE "MATERIAL"), INCLUDING WITHOUT LIMITING THE FOREGOING, ANY REPRESENTATION OR WARRANTY REGARDING THE USE OF THIS KIT OR ANY RESULTS PRODUCED FROM ITS USE, THAT THIS KIT OR ANY OF THE MATERIAL WILL NOT INFRINGE ANY THIRD PARTY RIGHTS OR THAT THE MATERIAL IS ACCURATE OR COMPLETE OR THAT THIS KIT IS OF MERCHANTABLE QUALITY OR IS FIT FOR ANY PARTICULAR PURPOSE.

bioLytical EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY WHATSOEVER FOR ANY DAMAGES, WHETHER DIRECT, INDIRECT, SPECIAL, PROXIMATE, CONSEQUENTIAL OR OTHERWISE, INCLUDING INJURY TO PERSONS OR PROPERTY, DEATH, CONTAMINATION AND ANY OTHER ADVERSE CONSEQUENCES, RESULTING IN ANY WAY FROM THE USE OF THIS KIT OR ANY OTHER OF THE MATERIAL, OR FROM ANY ERRORS OR OMISSIONS IN THE MATERIAL AND ANY ERRORS OR DEFECTS IN, OR FAILURE OF, THIS KIT, WHETHER CLAIMED IN CONTRACT, NEGLIGENCE OR ANY OTHER CAUSE OF ACTION. IN NO EVENT WILL bioLytical's LIABILITY EXCEED THE AMOUNT PAID FOR THIS KIT.

USERS ARE WARNED THAT THIS KIT IS INTENDED ONLY TO BE USED BY, AND TO SUPPLEMENT THE INFORMED JUDGMENT OF, APPROPRIATELY QUALIFIED MEDICAL PERSONNEL. USERS ASSUME SOLE RESPONSIBILITY FOR THE USE OF THIS KIT, INCLUDING ALL RESPONSIBILITY FOR DETERMINING THE APPROPRIATENESS OF ITS USE IN ANY PARTICULAR SITUATION, FOR ANY CONCLUSIONS DRAWN FROM THE RESULTS OF ITS USE AND FOR ANY ACTIONS TAKEN OR NOT TAKEN AS A CONSEQUENCE OF THE RESULTS OF THIS KIT.

Reference herein to any specific third party by name, trade name, trademark, manufacturer or otherwise does not constitute or imply an endorsement or recommendation of this Kit by such third party, or of the products or services of such third party by bioLytical or that such products or services are necessarily best suited for the intended purpose.

 Manufactured by:



BioLytical™ Laboratories Inc.

13351 Commerce Parkway, Suite 1108
Richmond, British Columbia V6V 2X7
Canada

Toll Free: 1-866-674-6784

Phone: +1 604-204-6784

Fax: +1 604-244-8399

www.biolytical.com

50-1037 G

© Copyright 2009, All rights reserved.

Authorized Representative:

EC	REP	EMERGO EUROPE Molenstraat 15, 2513 BH, The Hague, The Netherlands Phone: +31.70.345.8570 Fax: +31.70.346.7299
----	-----	--